According to a recent report by Reports and Data, the global Therapy BCG market size is projected to reach USD 73.02 million by 2028, with a compound annual growth rate (CAGR) of 4.5% during the forecast period. This growth is attributed to various factors, including the increasing focus on BCG revaccination approach, rising demand for Therapy BCG to combat the increasing prevalence of tuberculosis, rising emphasis on immunization in emerging economies, and technological advancements in vaccine and drug development processes.

Therapy BCG is made from a strain of attenuated live Mycobacterium bovis found in cows, which does not cause disease in humans. It is primarily used to prevent tuberculosis and other infections caused by Mycobacterium species. Therapy BCG is safe, does not cause severe complications, and is the only vaccine available that can prevent tuberculosis. The vaccine is also used to protect against non-tuberculosis mycobacterial infections such as leprosy and in the treatment of superficial carcinoma of the bladder.

Get a sample PDF of the report, visit @

https://www.reportsanddata.com/download-free-sample/30

Tuberculosis is one of the major causes of death worldwide, with higher prevalence in communities facing socioeconomic challenges. Increasing investment to accelerate research to understand mycobacterial immunology and develop strategies to prevent pulmonary tuberculosis in adolescents and adults has significantly contributed to market growth. Development of efficacy clinical trials to evaluate potential of Therapy BCG in preventing sustained Mycobacterium tuberculosis infections in high-risk population is also expected to contribute to revenue growth of the market going ahead.

Therapy BCG is parenterally administered to infants worldwide, primarily in countries with a high prevalence of tuberculosis, as part of the Expanded Program on Immunization by the World Health Organization. In addition, Therapy BCG has several beneficial off-target effects on the immune system that confer protection against a broad spectrum of other infections such as chest infections and diarrhea, among others. This is another key factor expected to fuel demand for Therapy BCG and drive market growth over the forecast period.

However, global shortage of Therapy BCG, manufacturing and supply chain problems, and ineffectiveness of Therapy BCG in controlling the tuberculosis epidemic are some key factors expected to restrain market growth to a certain extent over the forecast period.

To know more about the latest insights of the report, visit @

https://www.reportsanddata.com/request-latest-insight/30

The immune Therapy BCG segment is expected to account for the largest revenue share over the forecast period, attributable to increasing administration of Therapy BCG in neonates and young children to provide protection against childhood tuberculosis meningitis. The pediatric segment is expected to register a robust revenue CAGR over the forecast period owing to a sharp increase in birth rates across the globe, growing focus on development of robust TB control programs, rising demand for Therapy BCG to prevent childhood tuberculosis, and emphasis on mandatory vaccination of neonates and young children.

The hospital segment is expected to register significant revenue growth over the forecast period, attributed to increasing availability of vaccine in hospital settings, immunization of newborn babies, favorable reimbursement policies, availability of skilled professionals and advanced healthcare facilities, and implementation of TB control strategies in hospital settings.

North America is expected to register considerable revenue growth over the forecast period owing to rising focus on immunization of children and newborn babies in the United States, availability of cost-effective vaccine, and increasing initiatives to promote vaccination in the region.

Major companies included in the market report are Merck & Co., Inc., Sanofi Pasteur, Japan BCG Laboratory, China National Biotec Group, Serum Institute of India Pvt. Ltd., InterVax Ltd., GreenSignal Bio Pharma Limited (GSBPL), and Statens Serum Institut. The Therapy BCG market is segmented based on type, application, end use, and region.

Request a customized copy of the report @

https://www.reportsanddata.com/request-customization-form/30

Thank you for reading our report. To inquire about customization or any query about the report, please get in touch with us. Our team will make sure the report is best suited to your needs.  

About Reports and Data 

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behaviour shifts across demographics, across industries, and help clients to make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Products, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.

Contact:

John W, Head of Business Development
Reports And Data | Web: www.reportsanddata.com
Direct Line: +1-212-710-1370
E-mail: [email protected]
LinkedIn | Twitter | Blogs

Browse for more reports…

https://www.reportsanddata.com/report-detail/dental-practice-management-software-market

https://www.reportsanddata.com/report-detail/diagnostic-imaging-equipment-market